Effect of genetic variation on side-effects of HIV drugs

In addition to drug levels, the other major area of research interest in pharmacogenetics is the association of human genetic variation with the incidence or severity of drug side-effects. In HIV treatment, some of these are directly related to elevated drug levels, such as the impact of metabolising enzymes on levels of efavirenz (Sustiva) and increased severity of neurological side-effects.

Genetic testing also has the potential to identify patients who are at risk of severe or life-threatening effects of drugs. The clinical benefit of this capability is obvious and has been demonstrated by the successful introduction of haplotype testing to reduce incidence of patients experiencing hypersensitivity reactions to the nucleoside reverse transcriptase inhibitor (NRTI) abacavir (Ziagen).

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.